Panitumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Epidermal growth factor receptor (EGFR) |
| Clinical data | |
| Trade names | Vectibix |
| Other names | ABX-EGF |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607066 |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | ~9.4 days (range: 4-11 days) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C6398H9878N1694O2016S48 |
| Molar mass | 144324.12 g·mol−1 |
| (what is this?) (verify) | |
Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).[1][2]
Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.
In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.[3]
- ^ a b "Vectibix- panitumumab solution". DailyMed. 25 August 2021. Archived from the original on 6 April 2022. Retrieved 6 July 2022.
- ^ a b "Vectibix EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 13 August 2021. Retrieved 6 July 2022.
- ^ "Illumina, Amgen to Develop CDx for Colorectal Cancer". News: Molecular Diagnostics. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. February 15, 2014. p. 32. Archived from the original on September 19, 2016. Retrieved December 2, 2014.